The Meet Group, Inc. (NASDAQ:MEET)

The Meet Group, Inc. is a social media technology company. It offers information sharing, social interaction and mobile application development services. The company’s app consists of currently MeetMe (R), Skout(R), Tagged(R) and Hi5(R). The Meet Group Inc., formerly known as MeetMe Inc., is headquartered in New Hope, Pennsylvania.

The Meet Group, Inc. (NASDAQ:MEET)’s Financial Overview

The Meet Group, Inc. (NASDAQ) surged 0% yesterday to close its trading session at $4.01. The company has 1 year Price Target of $6.58. The Meet Group, Inc. has 52-Week high of $5.63 and 52-Week Low of $1.84. The stock touched its 52-Week High on 5.63 and 52-Week Low on 1.84. The stock traded with the volume of 1.16 Million shares yesterday. The firm shows the market capitalization of $293.53 Million.

The Meet Group, Inc. (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $0.1/share against the analyst consensus estimate of $0.08/share. The difference between the actual and expected EPS is $0.02 a share with a surprise factor of 25%.

The firm is trading with SMA20 of 0.89 Percent, SMA50 of -9.15 Percent and SMA200 of 7 percent. The Meet Group, Inc. has P/S value of 1.77 while its P/B value stands at 1.55. Similarly, the company has Return on Assets of -26.6 percent, Return on Equity of -38.3 percent and Return on Investment of -23.1 Percent. The company shows Gross Margin and Operating Margin of 0 percent and -34.3 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 1.7 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 3 analysts offering 12-month price forecasts for Meet Group Inc have a median target of 6.75, with a high estimate of 7.00 and a low estimate of 6.00. The median estimate represents a +68.33% increase from the last price of 4.01.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Ohr Pharmaceutical, Inc. (NASDAQ:OHRP)

Ohr Pharmaceutical, Inc. is a pharmaceutical company. It is focused on the development of novel therapeutics for the treatment of cancer cachexia, wet form of age-related macular degeneration and ophthalmic neovascularization disorders. Ohr Pharmaceutical, Inc. is headquartered in New York.

Ohr Pharmaceutical, Inc. (NASDAQ:OHRP)’s Financial Outlook

The 1 analysts offering 12-month price forecasts for OHR Pharmaceutical Inc have a median target of 0.40, with a high estimate of 0.40 and a low estimate of 0.40. The median estimate represents a +198.06% increase from the last price of 0.13.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

The Stock declined -12.4% and closed its last trading session at $0.13. The company has the market capitalization of $8.23 Million. The stock has 52-week high of $2.18 and 52-Week low of $0.12. The firm touched its 52-Week high on 2.18 and 52-Week low on 0.14. The company has volume of 1.46 Million shares. The company has a total of 61.33 Million shares outstanding.

Ohr Pharmaceutical, Inc. (NASDAQ) in the last quarter reported its actual EPS of $-0.05/share where the analyst estimated EPS was $-0.07/share. The difference between the actual and Estimated EPS is $0.02. This shows a surprise factor of 28.6 percent.

The company has YTD performance of -92.78 percent. Beta for Ohr Pharmaceutical, Inc. stands at -0.05 while its ATR (average true range) is 0.02. The company has Weekly Volatility of 12.87%% and Monthly Volatility of 9.94%%.

Ohr Pharmaceutical, Inc. has distance from 20-day Simple Moving Average (SMA20) of -25.49%, Distance from 50-Day Simple Moving Average of -34.18 percent and Distance from 200-Day Simple Moving Average of -35.73%.

The Company currently has ROA (Return on Assets) of -54.6 percent, Return on Equity (ROE) of -62.7 Percent and Return on Investment (ROI) of 0% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *